NCT02457962 Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study
| NCT ID | NCT02457962 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | Solid Tumors |
| Study Type | OBSERVATIONAL |
| Enrollment | 15,000 participants |
| Start Date | 2015-04-23 |
| Primary Completion | 2031-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 15,000 participants in total. It began in 2015-04-23 with a primary completion date of 2031-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To collect and analyze specimens that will correlate with clinical outcomes such as acute and late toxicities, quality of life, local control, and survival of patients treated with photon/proton therapy.
Eligibility Criteria
Inclusion Criteria: 1. Treated with photon/proton at Mayo Clinic Rochester in Radiation Oncology 2. Radiation therapy for curative intent Exclusion Criteria: None
Contact & Investigator
Nadia N. Laack, MD
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT02457962 clinical trial?
This trial is open to participants of all sexes, studying Solid Tumors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02457962 currently recruiting?
Yes, NCT02457962 is actively recruiting participants. Contact the research team at mayocliniccancerstudies@mayo.edu for enrollment information.
Where is the NCT02457962 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT02457962 clinical trial?
NCT02457962 is sponsored by Mayo Clinic. The principal investigator is Nadia N. Laack, MD at Mayo Clinic. The trial plans to enroll 15,000 participants.